These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8237831)

  • 21. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of sotalol and class I antiarrhythmic agents in patients with ventricular tachycardia or fibrillation: results of the Electrophysiology Study Versus Electrocardiographic Monitoring (ESVEM) Trial.
    Klein RC
    Eur Heart J; 1993 Nov; 14 Suppl H():78-84. PubMed ID: 8293756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemodynamic effects of antiarrhythmic compounds: intrinsic effects and autonomic modulation.
    Hoffmeister HM; Beyer ME; Seipel L
    Am J Cardiol; 1997 Oct; 80(8A):24G-30G. PubMed ID: 9354409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there a need for new antiarrhythmic drugs?
    Roden DM
    Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():13-8. PubMed ID: 8734158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of drug therapy for sustained ventricular tachyarrhythmias.
    Mitchell LB
    Cardiol Clin; 2008 Aug; 26(3):405-18, vi. PubMed ID: 18538187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators.
    Mason JW
    N Engl J Med; 1993 Aug; 329(7):452-8. PubMed ID: 8332150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs.
    Kowey PR; Marinchak RA; Rials SJ; Bharucha D
    Am J Cardiol; 1997 Oct; 80(8A):16G-23G. PubMed ID: 9354408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of alterations in refractoriness and conduction in the genesis of reentrant arrhythmias. Implications for antiarrhythmic effects of class III drugs.
    Wit AL; Coromilas J
    Am J Cardiol; 1993 Nov; 72(16):3F-12F. PubMed ID: 8237828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction: changing trends in antiarrhythmic therapy: worldwide experience with class III agents.
    Singh BN; Breithardt G
    Am J Cardiol; 1997 Oct; 80(8A):1G-3G. PubMed ID: 9354406
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel antiarrhythmic compounds with combined class IB and class III mode of action.
    Mátyus P; Varga I; Rettegi T; Simay A; Kállay N; Károlyházy L; Kocsis A; Varró A; Pénzes I; Papp JG
    Curr Med Chem; 2004 Jan; 11(1):61-9. PubMed ID: 14754426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symposium on the management of ventricular dysrhythmias. Antifibrillatory versus antiectopic therapy.
    Anderson JL
    Am J Cardiol; 1984 Jul; 54(2):7A-13A. PubMed ID: 6147079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemodynamic effects of the class III antiarrhythmic drug, d-sotalol, in patients with congestive heart failure.
    Gottlieb SS; Singh S; Munger M; Eichhorn EJ; Ilgenfritz J; Hanyok J
    Am J Cardiol; 1996 Dec; 78(12):1411-5. PubMed ID: 8970416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease.
    Khalighi K; Peters RW; Feliciano Z; Shorofsky SR; Gold MR
    Am J Cardiol; 1997 Sep; 80(5):591-4. PubMed ID: 9294987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sotalol: the mechanism of its antiarrhythmic-defibrillating effect.
    Manoach M; Tribulova N
    Cardiovasc Drug Rev; 2001; 19(2):172-82. PubMed ID: 11484069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of antiarrhythmic drug effects by beta-adrenergic sympathetic stimulation.
    Sager PT
    Am J Cardiol; 1998 Aug; 82(4A):20I-30I. PubMed ID: 9737651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Future of antiarrhythmic drugs.
    Darbar D; Roden DM
    Curr Opin Cardiol; 2006 Jul; 21(4):361-7. PubMed ID: 16755206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Class-I antiarrhythmic drugs].
    Kuga K; Sugishita Y
    Nihon Rinsho; 1996 Aug; 54(8):2110-6. PubMed ID: 8810785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting antiarrhythmic performance.
    Pratt CM
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):302-6. PubMed ID: 10090236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia.
    Buchanan LV; Kabell G; Brunden MN; Gibson JK
    J Cardiovasc Pharmacol; 1993 Oct; 22(4):540-9. PubMed ID: 7505355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.